Skip to content

Exhaled NO Testing in Filariasis

Exhaled NO Testing in Filariasis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01628497
Enrollment
96
Registered
2012-06-26
Start date
2012-05-31
Completion date
2014-03-31
Last updated
2017-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Filariasis

Brief summary

This study is looking at the difference in exhaled nitric oxide levels in patients with and without laboratory evidence of filariasis.

Interventions

None listed

Sponsors

Vanderbilt University Medical Center
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
6 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Age 6 years or older of either gender 2. Patients presenting with pulmonary symptoms a. Confirmed or suspected asthma patients: i. Patients presenting with symptoms consistent with an acute exacerbation of asthma, including: 1\. Wheezing 2. Shortness of breath 3. Chest tightness 4. Cough ii. Disposition to the asthma room after triage and physician evaluation (disposition to other areas of the A&E allowed if due to no available space in the asthma room) iii. Patients are potentially eligible with or without a past history of health care provider diagnosed asthma iv. Patients are potentially eligible regardless of the number of previous episodes of wheezing (i.e. patients with a first episode of bronchospasm are potentially eligible) v. If suspected or documented to have pneumonia or a pulmonary infiltrate, patients are potentially eligible if: 1. They have a dry cough (no production of purulent sputum) 2. They have bronchospasm as manifested by wheezing or need for salbutamol (albuterol) breathing treatments vi. Patients with wheezing are not eligible if they: 1\. Have purulent sputum production 2. Have known or suspected: a. Tuberculosis b. Immunodeficiency c. Congestive heart failure d. Foreign body aspiration b. Patients presenting with a chief complaint of cough: i. Potentially eligible patients will have a cough of greater than one week (seven days) duration ii. Asthma room disposition is not required for these subjects iii. If suspected or documented to have pneumonia or a pulmonary infiltrate, patients are potentially eligible if: 1\. They have a dry cough (no production of purulent sputum) iv. Patients with cough are not eligible if: 1. Have purulent sputum production 2. Have known or suspected: 1. Tuberculosis 2. Immunodeficiency 3. Congestive heart failure 4. Foreign body aspiration 3. Patients will be medically stable at the time of the consent process (see

Exclusion criteria

below) 4. A minimum of 2 years of continuous residence in Guyana at the time of enrollment, exclusive of short trips out of the country (at least 21 of previous 24 months physically in Guyana) 5. English speaking

Countries

Guyana

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026